AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3723287 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPS program (alcohol misuse prevention study) consisting of four sessions focusing on immediate effects of alcohol, risks of alcohol misuse, and social pressures to misuse alcohol.
Number of subjects: 5635
Study 3723287 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPS program (alcohol misuse prevention study)
Number of subjects: 5635
Study 3723287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5635
Study 31577449 — intervention group
Group type: EXPERIMENTAL
Intervention: PainCheck e-health tool for pain management
Number of subjects: 0
Study 29988111 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab followed by chemotherapy (FLOT)
Number of subjects: 31
Study 29988111 — intervention group
Group type: COMPARATOR
Intervention: FLOT alone
Number of subjects: 31
Study 26813241 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 194
Study 25188566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic interpersonal group psychotherapy (DIGP), 16 sessions held weekly
Number of subjects: 0
Study 25188566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22551950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-complex carbohydrate diets (LFHCC)
Number of subjects: 42
Study 19725896 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 18607743 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive correction costume
Number of subjects: 23
Study 16029682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 4-ethoxybenzaldehyde
Number of subjects: 30
Study 16029682 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 30
Study 11814530 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 338
Study 11814530 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 338
Study 11814530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 10521742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg)
Number of subjects: 50
Study 10521742 — intervention group
Group type: COMPARATOR
Intervention: Intravenous labetalol (20 mg)
Number of subjects: 50
Study 8928194 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (topical nasal drop of 0.1% betamethasone for 12 patients and oral administration of prednisolone for 5 patients)
Number of subjects: 20
Study 8928194 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 1505264 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy-Flow drain
Number of subjects: 80
Study 1505264 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 80
Study 6388588 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose load with 50 g ethanol
Number of subjects: 14
Study 6388588 — intervention group
Group type: COMPARATOR
Intervention: Starch solution (maize meal) and alcohol
Number of subjects: 14
Study 30678670 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention group (CyFiT OPS)
Number of subjects: 110
Study 30678670 — intervention group
Group type: COMPARATOR
Intervention: Usual Outpatient Physiotherapy Service group (Usual OPS)
Number of subjects: 110
Study 30678670 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CyFiT OPS and Usual OPS)
Number of subjects: 110
Study 29138226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12
Study 29138226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24989993 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosetta system
Number of subjects: 0
Study 25060690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ethanol intervention
Number of subjects: 39
Study 22235808 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus 12 weekly music therapy sessions delivered by the Northern Ireland Music Therapy Trust
Number of subjects: 200
Study 22235808 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200
Study 20929718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-mild self-etch adhesive
Number of subjects: 0
Study 20929718 — intervention group
Group type: EXPERIMENTAL
Intervention: Lab-SiC-prepared surface
Number of subjects: 0
Study 20929718 — intervention group
Group type: COMPARATOR
Intervention: Bur-prepared surface
Number of subjects: 0
Study 18598321 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 10
Study 18598321 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular pacing
Number of subjects: 10
Study 18598321 — intervention group
Group type: COMPARATOR
Intervention: LV pacing
Number of subjects: 10
Study 15947764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed wave Doppler tissue imaging
Number of subjects: 87
Study 15947764 — intervention group
Group type: EXPERIMENTAL
Intervention: E/Em ratio greater than 9
Number of subjects: 87
Study 11895049 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam and lovastatin coadministered with dinner
Number of subjects: 22
Study 11895049 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam with dinner and lovastatin 4 hours later with a snack
Number of subjects: 22
Study 11895049 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin alone administered with dinner
Number of subjects: 22
Study 10516540 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 22
Study 10516540 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 22
Study 10516540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8544722 — intervention group
Group type: EXPERIMENTAL
Intervention: CFM (480 ml)
Number of subjects: 30
Study 8544722 — intervention group
Group type: COMPARATOR
Intervention: RM (480 ml)
Number of subjects: 30
Study 1952848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (n = 63)
Number of subjects: 194
Study 1952848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (n = 66)
Number of subjects: 194
Study 1952848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (n = 60)
Number of subjects: 194
Study 7002830 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Mianserin
Number of subjects: 12
Study 7002830 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg Mianserin
Number of subjects: 12
Study 7002830 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg Mianserin
Number of subjects: 12
Study 31291786 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 31291786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 28369971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirasol-treated RBCs
Number of subjects: 24
Study 28369971 — intervention group
Group type: COMPARATOR
Intervention: Untreated RBCs (Control)
Number of subjects: 24
Study 26014129 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG and mitomycin
Number of subjects: 500
Study 26014129 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 500
Study 24359456 — intervention group
Group type: EXPERIMENTAL
Intervention: COSTRIDE intervention
Number of subjects: 219
Study 24359456 — intervention group
Group type: COMPARATOR
Intervention: HW intervention (control)
Number of subjects: 219
Study 22722961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 20
Study 22722961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 20
Study 22722961 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 20
Study 19786805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 66
Study 19786805 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control)
Number of subjects: 66
Study 17442226 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 0
Study 17442226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Number of subjects: 0
Study 17442226 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0
Study 17442226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing trials
Number of subjects: 0
Study 16332656 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH + IDPN + exercise
Number of subjects: 7
Study 16332656 — intervention group
Group type: COMPARATOR
Intervention: IDPN + exercise
Number of subjects: 7
Study 12145434 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + calcipotriol ointment (50 microg/g), applied twice daily
Number of subjects: 143
Study 12145434 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid ester (FAE) tablets (Fumaderm) with increasing daily dosage from 105 to 1,075 mg + ointment vehicle
Number of subjects: 143
Study 9689424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol + DSCG by HFA-MDI
Number of subjects: 24
Study 9689424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol + DSCG by CFC-MDI
Number of subjects: 24
Study 9689424 — intervention group
Group type: COMPARATOR
Intervention: Placebo by HFA-MDI
Number of subjects: 24
Study 9689424 — intervention group
Group type: COMPARATOR
Intervention: Placebo by CFC-MDI
Number of subjects: 24
Study 7985634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet M (high in myristic acid)
Number of subjects: 12
Study 7985634 — intervention group
Group type: COMPARATOR
Intervention: Diet P (high in palmitic acid)
Number of subjects: 12
Study 3143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 61
Study 3143482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergotamine tartrate compound
Number of subjects: 61
Study 29488226 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg Q2W
Number of subjects: 493
Study 29488226 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 493
Study 26850809 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (18 sessions, 3 times per week, 1 hour per session)
Number of subjects: 47
Study 26850809 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 25594355 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion with active substances (hyaluronic acid, sericin, glycerol, urea)
Number of subjects: 20
Study 25594355 — intervention group
Group type: COMPARATOR
Intervention: Gel with active substances (hyaluronic acid, sericin, glycerol, urea)
Number of subjects: 20
Study 21945402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 34
Study 21945402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20819579 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 800
Study 17310359 — intervention group
Group type: COMPARATOR
Intervention: dDAVP
Number of subjects: 151
Study 17310359 — intervention group
Group type: COMPARATOR
Intervention: Homotoxicological remedies
Number of subjects: 151
Study 17310359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 16514482 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (5, 15, or 25 mcg/m2 on days 1, 8, and 15 starting in the second cycle)
Number of subjects: 33
Study 16514482 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (11 x 10(6) IU subcutaneously on days 1-4, 8-11, and 15-18 of every 28-day cycle) + Bryostatin-1 (35 mcg/m2, non-randomized)
Number of subjects: 33
Study 12966426 — intervention group
Group type: EXPERIMENTAL
Intervention: No HPV
Number of subjects: 93
Study 12966426 — intervention group
Group type: COMPARATOR
Intervention: With HPV
Number of subjects: 93
Study 12966426 — intervention group
Group type: EXPERIMENTAL
Intervention: Five or fewer lifetime sexual partners
Number of subjects: 93
Study 12966426 — intervention group
Group type: COMPARATOR
Intervention: More than five lifetime sexual partners
Number of subjects: 93
Study 10481115 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 100
Study 10481115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8892674 — intervention group
Group type: EXPERIMENTAL
Intervention: VDJ rearrangements derived by PCR with VH gene family‐specific primers
Number of subjects: 32
Study 8892674 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of rearrangements in one patient at first bone marrow relapse
Number of subjects: 32
Study 8892674 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of absent N nucleotides in the DJ border
Number of subjects: 32
Study 8892674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing of more than one rearrangement
Number of subjects: 32
Study 1994537 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 25
Study 1994537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6661620 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg)
Number of subjects: 19
Study 6661620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg)
Number of subjects: 19
Study 6661620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31642526 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied behavior analytic intervention
Number of subjects: 6
Study 31642526 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 6
Study 29426320 — intervention group
Group type: EXPERIMENTAL
Intervention: SPEEDI (Supporting Play Exploration and Early Development Intervention)
Number of subjects: 14
Study 29426320 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14
Study 27224642 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 4055
Study 27224642 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4055
Study 27224642 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-economic analysis of LDCT screening
Number of subjects: 4055
Study 24293405 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified visual quantitative score (SQS) of late gadolinium enhancement (LGE)
Number of subjects: 28
Study 24293405 — intervention group
Group type: COMPARATOR
Intervention: Initial hospitalization characteristics
Number of subjects: 28
Study 22173570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.1 μg/kg/min for 10 min loading dose, followed by 0.4 μg/kg/h continuous infusion
Number of subjects: 32
Study 22173570 — intervention group
Group type: COMPARATOR
Intervention: Propofol 0.1 mg/kg/min for 10 min loading dose, followed by 1 mg/kg/h continuous infusion
Number of subjects: 32
Study 19906800 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Ca/d
Number of subjects: 323
Study 19906800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg Ca/d
Number of subjects: 323
Study 19906800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 17140871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen (supervised, progressive, three times per week)
Number of subjects: 120
Study 17140871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen (most active exercisers >66 sessions)
Number of subjects: 120
Study 17140871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise regimen
Number of subjects: 120
Study 17140871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 120
Study 15390196 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSD (computerized pressure‐specific sensory device)
Number of subjects: 41
Study 15390196 — intervention group
Group type: EXPERIMENTAL
Intervention: SWM (Semmes Weinstein Monofilament)
Number of subjects: 41
Study 15390196 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSD
Number of subjects: 41
Study 15390196 — intervention group
Group type: COMPARATOR
Intervention: SWM and PSSD
Number of subjects: 41
Study 12628633 — intervention group
Group type: EXPERIMENTAL
Intervention: group CBT (n = 10)
Number of subjects: 30
Study 12628633 — intervention group
Group type: COMPARATOR
Intervention: psychological placebo intervention (i.e., emotional disclosure [ED]; n = 10)
Number of subjects: 30
Study 12628633 — intervention group
Group type: COMPARATOR
Intervention: no‐treatment control condition (n = 10)
Number of subjects: 30
Study 9658756 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNPEP HCV‐EIA II
Number of subjects: 0
Study 7632029 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem-trimetazidine (60 mg/24 h)
Number of subjects: 67
Study 7632029 — intervention group
Group type: COMPARATOR
Intervention: diltiazem-placebo
Number of subjects: 67
Study 2792112 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine
Number of subjects: 46
Study 2792112 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nicardipine
Number of subjects: 46
Study 339788 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol
Number of subjects: 18
Study 339788 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol aerosol
Number of subjects: 18
Study 339788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29153546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation for 48 weeks
Number of subjects: 53
Study 29153546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 30074327 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg of clonidine with hyperbaric bupivacaine (BC15 group)
Number of subjects: 105
Study 30074327 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of clonidine with hyperbaric bupivacaine (BC30 group)
Number of subjects: 105
Study 30074327 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg of clonidine with hyperbaric bupivacaine (BC60 group)
Number of subjects: 105
Study 30074327 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine alone (Control not explicitly mentioned)
Number of subjects: 105
Study 25682602 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg/day for grade IIa manifestations
Number of subjects: 164
Study 25682602 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 0.5 mg/kg/day for grade IIa manifestations
Number of subjects: 164
Study 25682602 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/kg/day for grade IIb or higher manifestations
Number of subjects: 164
Study 25682602 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 1 mg/kg/day for grade IIb or higher manifestations
Number of subjects: 164
Study 23947388 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational hand washing intervention
Number of subjects: 0
Study 23947388 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20454943 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ganciclovir (5 mg/kg twice daily for 1 week)
Number of subjects: 68
Study 20454943 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ganciclovir (5 mg/kg twice daily for 1 week)
Number of subjects: 68
Study 20454943 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ganciclovir
Number of subjects: 68
Study 20454943 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ganciclovir
Number of subjects: 68
Study 18208428 — intervention group
Group type: EXPERIMENTAL
Intervention: The '11' exercise program, a 15-min warm-up for football training, used over an 8-month season.
Number of subjects: 2092
Study 18208428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 2092
Study 15230706 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcortical approach
Number of subjects: 80
Study 15230706 — intervention group
Group type: COMPARATOR
Intervention: Transsylvian approach
Number of subjects: 80
Study 15230706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 80
Study 12019196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (125 mg, 100 micro Ci) in healthy subjects
Number of subjects: 2
Study 12019196 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (142 mg, 100 micro Ci) in cholecystectomy patients
Number of subjects: 2
Study 9808550 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus PUVA
Number of subjects: 82
Study 9808550 — intervention group
Group type: COMPARATOR
Intervention: IFN plus acitretin
Number of subjects: 82
Study 7621843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg nocte
Number of subjects: 152
Study 7621843 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol CR 8 mg b.i.d.
Number of subjects: 152
Study 2930745 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburethral sling
Number of subjects: 20
Study 2930745 — intervention group
Group type: COMPARATOR
Intervention: Stamey endoscopic bladder neck suspension
Number of subjects: 20
Study 2930745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 20
Study 2930745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling procedure
Number of subjects: 20
Study 2930745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stamey procedure
Number of subjects: 20
Study 798127 — intervention group
Group type: EXPERIMENTAL
Intervention: Elantrine
Number of subjects: 0
Study 31633738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, Family-Involved Hospital Elder Life Program (t-HELP)
Number of subjects: 281
Study 31633738 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 281
Study 31238421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab only (RBZ group)
Number of subjects: 32
Study 31238421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab with UWFFA-guided laser (RBZ + TRP group)
Number of subjects: 32
Study 31238421 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32